Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Pierre-Étienne Heudel; Sylvie Chabaud; David Pérol; Aude Fléchon; Jérôme Fayette; P. Combemale; Olivier Trédan; Françoise Desseigne; Christelle de la Fouchardière; H. Boyle; M. Pérol; Thomas Bachelot; Philippe A. Cassier; Virginie Avrillon; C. Terret; Anne‐Sophie Michallet; Eve‐Marie Neidhardt‐Berard; Emmanuelle Nicolas‐Virelizier; Armelle Dufresne; Amine Belhabri; M. Brahmi; Laure Lebras; Franck E. Nicolini; Matthieu Sarabi; Pablo Maroto Rey; Alice Bonneville-Levard; Pauline Rochefort; A.-M. Provensal; Lauriane Eberst; Souad Assaad; Aurélie Swalduz; Pierre Saintigny; Philippe Toussaint; Yann Guillermin; Marie Castets; Clélia Coutzac; Pierre Méeus; Aurélien Dupré; Thierry Durand; Hugo Crochet; Béatrice Fervers; F. Gómez; Michel Rivoire; V. Grégoire; L. Claude; Catherine Chassagne‐Clément; F. Pilleul; Thomas Mognetti; Bruno Russias; Jean-Luc Soubirou; Christine Lasset; Gisèle Chvetzoff; Patrick Mehlen; Sophie Beaupère; Philippe Zrounba; I. Ray-Coquard; Jean Yves Blay

doi:10.1016/j.esmoop.2020.100044

Related publications

Preprint2024

Real-World Evidence from the TriNetX Network: Assessing Immunotherapy's Impact on Second Primary Cancer Risk in Metastatic Lung Cancer (Preprint)

Pierre-Étienne Heudel, Gema Hernandez, Olivier Denquin, Hugo Crochet, Jean Yves Blay

Article2021

Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.

Evangelos Eleutherakis Papaiakovou, Efstathios Kastritis, Flora Zagouri, Dimitra Grapsa, Ioannis Ntanassis-Stathopoulos, Dimitra Stefanou, George Evangelou, Ilias Kotteas, Meletios A Dimopoulos, Konstantinos Syrigos

Article2022

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

Rohini Sharma, Anjana Pillai, Thomas U. Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, C.C. Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed O. Kaseb, Yi‐Hsiang Huang, Celina Ang, ,

Article2020

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma

Naoshi Nishida, Masatoshi Kudo

Article2021

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors

Christopher A. Muir, Alexander M. Menzies, Roderick Clifton‐Bligh, Georgina V. Long, Richard A Scolyer, Venessa Tsang